Foresite Capital Management VI LLC Diversified Active

CIK: 0002013341 · Show all filings

Period: Q4 2025 (← Previous)

Filing Date: Feb 17, 2026

Total Value ($000): $330,839 (100.0% shares, 0.0% debt)

Holdings (12)

New Positions (3)

NTRA Natera, Inc. 4.7%

Value ($000) $15,431 Shares 67,356 Est. Cost $208.59 Unrealized 0.0%

AGIO AGIOS PHARMACEUTICALS, INC. 4.4%

Value ($000) $14,427 Shares 530,000 Est. Cost $35.08 Unrealized 0.0%

— Atai Beckley N.V. 3.4%

Value ($000) $11,248 Shares 2,750,000 Est. Cost $4.09 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
NTRA	Natera, Inc.	67,356	$15,431	4.7%	$208.59	0.0%	COM	632307104
AGIO	AGIOS PHARMACEUTICALS, INC.	530,000	$14,427	4.4%	$35.08	0.0%	COM	00847X104
—	Atai Beckley N.V.	2,750,000	$11,248	3.4%	$4.09	—	SHS	N0731H103

Increased Positions (2)

CNTA Centessa Pharmaceuticals plc 10.3%

Value ($000) $34,114 (+7.1%) Shares 1,364,019 (+3.8%) Est. Cost $17.39 Unrealized —

VSTM Verastem, Inc. 7.3%

Value ($000) $24,203 (+4.8%) Shares 3,135,120 (+19.9%) Est. Cost $7.21 Unrealized +23.7%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CNTA	Centessa Pharmaceuticals plc	1,364,019 (+3.8%)	$34,114 (+7.1%)	10.3%	$17.39	—	SPONSORED ADS	152309100
VSTM	Verastem, Inc.	3,135,120 (+19.9%)	$24,203 (+4.8%)	7.3%	$7.21	+23.7%	COM	92337C203

Exited Positions (3)

— Akero Therapeutics, Inc. 3.5%

Value ($000) $11,628 Shares 244,900 Est. Cost $27.82 Unrealized —

RNA Avidity Biosciences, Inc. 0.5%

Value ($000) $1,743 Shares 40,000 Est. Cost $29.81 Unrealized +116.7%

CASI CASI Pharmaceuticals, Inc. 0.5%

Value ($000) $1,627 Shares 979,956 Est. Cost $4.16 Unrealized -68.9%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Akero Therapeutics, Inc.	244,900	$11,628	3.5%	$27.82	—	—	00973Y108
RNA	Avidity Biosciences, Inc.	40,000	$1,743	0.5%	$29.81	+116.7%	—	05370A108
CASI	CASI Pharmaceuticals, Inc.	979,956	$1,627	0.5%	$4.16	-68.9%	—	G1933S101

Decreased Positions (1)

CRVS Corvus Pharmaceuticals, Inc. 3.2%

Value ($000) $10,635 (-16.6%) Shares 1,381,233 (-20.2%) Est. Cost $7.13 Unrealized +10.5%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CRVS	Corvus Pharmaceuticals, Inc.	1,381,233 (-20.2%)	$10,635 (-16.6%)	3.2%	$7.13	+10.5%	COM	221015100

Unchanged Positions (6)

ALMS ALUMIS INC. 12.5%

Value ($000) $41,457 Shares 4,247,670 Est. Cost $9.97 Unrealized -30.0%

RAPT RAPT Therapeutics, Inc. 16.0%

Value ($000) $52,922 Shares 1,562,500 Est. Cost $7.63 Unrealized +307.1%

KYMR Kymera Therapeutics, Inc. 3.4%

Value ($000) $11,386 Shares 146,332 Est. Cost $45.17 Unrealized +49.5%

CGON CG Oncology, Inc. 27.9%

Value ($000) $92,236 Shares 2,221,474 Est. Cost $34.21 Unrealized +21.0%

DNLI Denali Therapeutics Inc. 5.0%

Value ($000) $16,510 Shares 1,000,000 Est. Cost $14.37 Unrealized +17.5%

HNGE Hinge Health, Inc. 1.9%

Value ($000) $6,271 Shares 135,000 Est. Cost $40.42 Unrealized +19.1%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ALMS	ALUMIS INC.	4,247,670	$41,457	12.5%	$9.97	-30.0%	COM	022307102
RAPT	RAPT Therapeutics, Inc.	1,562,500	$52,922	16.0%	$7.63	+307.1%	COM	75382E208
KYMR	Kymera Therapeutics, Inc.	146,332	$11,386	3.4%	$45.17	+49.5%	COM	501575104
CGON	CG Oncology, Inc.	2,221,474	$92,236	27.9%	$34.21	+21.0%	COM	156944100
DNLI	Denali Therapeutics Inc.	1,000,000	$16,510	5.0%	$14.37	+17.5%	COM	24823R105
HNGE	Hinge Health, Inc.	135,000	$6,271	1.9%	$40.42	+19.1%	CL A	433313103